Board of Directors

Board of Directors

Gisela Sitbon

Born 1958
Chairperson of the board 
Board member since 2012, Chairperson since 2014

Education and training:

Doctorate in medical sciences from the Karolinska Institute in Solna

Main experience:

Twenty-five years of experience in the life science industry, of which just over ten years in senior positions (including CEO) at Professional Genetics Laboratory AB and five years as head of section at Karo Bio AB. Business coach in the life science sector at STING AB and responsible for business development for growth companies at her own company ZENZ AB.

Other board appointments:

Chairperson of the Board of Beactica Therapeutics AB and Gradientech AB. Board member of Annexin Pharmaceuticals AB, CollaboDoc AB, ENCare AB, In Singulo Solutions AB, and Sitbon Bioscience Partner Zenz AB.

Holds 20,000 shares through the company Sitbon Bioscience Partner Zenz AB

Mattias Bengtsson

Born 1969
Board member since 2019

EDUCATION AND TRAINING:

Master of Science in Chemical Engineering at Chalmers University of Technology in Gothenburg,  MBA at University of Gothenburg School of Business

MAIN EXPERIENCE:

More than 15 years of experience from AkzoNobel Pulp and Performance Chemicals AB, as General Manager Kromasil and Fine Chemicals, Manager Global Sales and Marketing, Manufacturing Manager and Product Category Manager. Currently CEO of Biolin Scientific AB.

OTHER BOARD APPOINTMENTS:

Board member of Biolin Scientific AB

Holds no shares in Nanologica

Eva Byröd

Born 1952
Board member since 2017

EDUCATION AND TRAINING:

Master of Science in Chemical Engineering Chalmers University of Technology

MAIN EXPERIENCE:

More than twenty-five years of experience as a line manager in pharmaceutical research and development and ten years’ experience as a Project Manager/Project Director, working in early as well as late phase pharmaceutical development projects.                                                                                          

OTHER BOARD APPOINTMENTS:

Board member of Eva Byröd Consulting AB and deputy board member of Bo Karlberg Arkitektur & Utveckling AB

Holds no shares in Nanologica 

Tomas Kramar

Born 1954
Board member since 2020

Education and training:

Master of Science in Chemical Engineering from Lund University of Technology

Main experience:

40 years’ experience of leading large companies, as well as start-ups. Most recently CEO in Sweden of Siemens Healthineers and before that CEO in Sweden for Siemens Healthcare Diagnostics. Tomas has also been a board member and chairman of the board in large and small companies.                                                                                      

Other board appointments:

Board member of Lundonia Biotech AB and Chairman of the board of T.M. Kramar Group AB.

Holds no shares in Nanologic

Anders Rabbe Board Member Nanologica AB

Anders Rabbe

Born 1970
Board member since 2020

Education and training:

Bachelor of Science in business administration from Webster University, Genève. 

Main experience:

Anders has been the CEO of several companies within the biotech and the financial sector. The last 10 years, Anders has held the position as CEO of Isofol Medical AB. Anders currently holds the position of CEO at Wntresearch AB.

Other board appointments:

Board member of Baricol Bariatrics AB, Investmentaktiebolaget Akkumula AB and Albonja AB.

Holds no shares in Nanologica An

Lena Torlegård Board Member Nanologica AB

Lena Torlegård

Born 1963
Board member since 2014

EDUCATION AND TRAINING:

Bachelor of Science in business administration from the Stockholm School of Economics

MAIN EXPERIENCE:

More than 20 years of experience as a communications consultant for a large number of companies, including companies in the life science industry. Lena now acts as advisor for financial and corporate communications with several clients in the life science sector through her company Lena Torlegård AB.

OTHER BOARD APPOINTMENTS:

Board member of Annexin Pharmaceuticals AB, CoDesignSweden AB, IRLAB Therapeutics AB, Integrative Research Laboratories Sweden AB and Synartro AB.

Holds 5,739 shares